Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK Correspondence to: Professor F Y Liew Division of Immunology, Infection and ...

OBJECTIVE To evaluate secular trends in the incidence and prevalence of rheumatoid arthritis (RA) in Japan. METHODS The incidence and prevalence of RA were determined in a longitudinal population ...

Leo van de Putte, UMC Nijmegen, Nijmegen, PO Box 9101, 6500 HB, The Netherlands; l.vandeputte{at}reuma.umcn.nl If you wish to reuse any or all of this article please ...

Department of Physiology, Yong Loo Lin School of Medicine, University of Singapore, Singapore Professor F Y Liew, Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre ...

MRC Environmental Epidemiology Unit, Community Clinical Sciences, University of Southampton, UK Correspondence to: Dr K T Palmer, MRC Environmental Epidemiology Unit, Southampton General Hospital, ...

1 Arthritis Research Campaign (arc) Epidemiology Unit, Division of Epidemiology and Health Sciences, University of Manchester, UK 2 Unit of Chronic Disease Epidemiology, Division of Epidemiology and ...

Objective: To examine the subjective health in patients with ankylosing spondylitis (AS) compared with the general population, and to explore the associations between health status and age, sex of the ...

Background: Patient reported outcome measures used in studies of psoriatic arthritis (PsA) have been found to be inadequate for determining the impact of the disease from the patient’s perspective.

Correspondence to Simon Rothwell, Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester M13 9PL, UK; s.rothwell{at}manchester.ac.uk Objectives Idiopathic ...

Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...